Jennerex Completes Treatment for First Patient Cohort in Phase I Cancer Study
Posted on: Friday, 17 October 2008, 12:00 CDT
Jennerex Biotherapeutics, a developer of cancer therapeutics, has completed treatment for the first patient cohort in the Phase I cancer clinical trial of its targeted poxvirus JX-594, delivered by intravenous infusion. No significant toxicities were reported, and treatment was well-tolerated.
The Phase I intravenous (IV) trial involves treatment of patients with advanced, metastatic solid tumors refractory to standard therapy. Patients receive treatment at one of five dose levels in a sequential dose-escalating design; the first cohort has now been treated safely.
Once the maximum tolerated dose is defined, an additional three to six patients will be enrolled at that dose level. The trial is being conducted initially at clinical sites in the US, and will subsequently open at sites in Canada.
The primary objective for this trial is to determine the maximum tolerated or feasible dose of JX-594 administered IV. In addition, IV delivery of JX-594 to solid tumors will be evaluated. An estimated total of 12 to 15 patients will be treated.
David Kirn, president and CEO of Jennerex, said: "We're very excited to have this trial open and enrolling with our lead product, JX-594. The safe delivery of JX-594 through intravenous administration is a major milestone for our company. Intravenous therapy allows treatment of major market cancers including non-small cell lung cancer. These data confirm the safety and feasibility of systemic dosing and tumor targeting that were reported in liver tumor patients treated previously."
Source: Datamonitor
Related Articles
- Advances in Radiation Therapy Enable Doctors to Improve the Quality of Treatments for Patients With Head and Neck Cancer
- First Patient Dosed in Phase 2 Clinical Trial of NKTR-102 in Ovarian Cancer
- Cancer Treatment Services of Casa Grande, Arizona, Begins Treating Cancer Patients Using Fast, Precise RapidArc(TM) Radiotherapy Technology
- Sirtex Supports the Fourth Annual Clinical Symposium on Liver-Directed Microsphere Therapy Dedicated to Advancing Treatments for Patients With Inoperable Metastatic Liver Cancer
- New Cancer Drug Satraplatin Predicted To Reach the Market in Mid 2007 for Second-Line Treatment of Patients With Hormone-Refractory Prostate Cancer
- FDA Approves Taxotere(R) for the Treatment of Patients With Head and Neck Cancer
- Taxotere(R) Receives U.S. FDA Approval for the Treatment of Patients With Head and Neck Cancer
- Medivation Announces First Patient Dosed in Phase II Trial With Dimebon for Treating Alzheimer's Disease
- Spectrum Pharmaceuticals Initiates U.S. Clinical Trial of Ozarelix (SPI-153) in Patients With Hormone-Dependent Prostate Cancer
- Spectrum Pharmaceuticals Launches, Phase 2 Multicenter, Clinical Trial of SPI-153 in Hormone-Dependent Prostate Cancer
 |
 |
User Comments (0)
RSS Feeds